BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-204@pharmaconomics
DTSTAMP:20260707T005012Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:RARE PDUFA — UX111 (rebisufligene etisparvovec) (estimated date)
DESCRIPTION:The FDA's approval decision on UX111 (rebisufligene etisparvovec) for Sanfilippo syndrome type A (MPS IIIA) is due ~ Sep 30\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1515673/000119312526030590/rare-20260130.htm\n\nTrack it: https://www.pharmaconomics.com/e/204
URL:https://www.pharmaconomics.com/e/204
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RARE catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR